MyomectomyPhase 4NCT04357015
Intravenous Tranexamic Acid Versus IV Carbetocin in Abdominal Myomectomy
A Phase 4 study testing intravenous tranexamic acid and intravenous carbetocin in people with Myomectomy, run by Cairo University.
Trial summary
the aim of the present study is to compare safety and efficacy of intravenous tranexamic acid versus IV carbetocin in reducing blood loss during abdominal myomectomy: a randomized controlled trial Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Myomectomy
- What is being tested?
- intravenous tranexamic acid and intravenous carbetocin
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 153 participants
- Where
- No sites listed yet
- Study dates
- 1 May 2020to 20 Oct 2020
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- women with symptomatic fibroids candidate for abdominal myomectomy with staging of myoma from (3 to 6) according to FIGO staging
Who cannot join
- women with Myoma FIGO staging (1,2,7 and 8) candidate for laparoscopic or hysteroscopic myomectomy, women with allergy or contraindications to carbetocin or tranexamic acid
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Comparative Safety and Efficacy of Intravenous Tranexamic Acid Versus IV Carbetocin in Reducing Blood Loss During Abdominal Myomectomy: a Randomized Controlled Trial
the aim of the present study is to compare safety and efficacy of intravenous tranexamic acid versus IV carbetocin in reducing blood loss during abdominal myomectomy: a randomized controlled trial
- Conditions
- Myomectomy
- Being tested
- intravenous tranexamic acid, intravenous carbetocin, placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
intravenous tranexamic acidDrug
The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
intravenous carbetocinDrug
The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
placeboDrug
the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
| Study group | Role | What they receive |
|---|---|---|
| intravenous tranexamic acid | Experimental | The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision Receives: Drug: intravenous tranexamic acid |
| intravenous carbetocin | Active comparator | The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision Receives: Drug: intravenous carbetocin |
| placebo | Placebo comparator | the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision Receives: Drug: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
intraoperative blood loss
the intraoperative blood loss in ml will be estimated during the procedure
Measured: one hour
Secondary outcomes (1)
need for blood transfusion
need for intraoperative or postoperative blood transfusion
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2020
- Study start1 May 2020 (estimated)
- Primary completion10 Oct 2020 (estimated)
- Study completion20 Oct 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MyomectomyStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 153 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Samy aly ashour, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04357015
- Sponsor's protocol ID
- tranexamic acid myomectomy
- Status last verified
- Apr 2020
- First submitted
- 20 Apr 2020
- Last updated
- 22 Apr 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Safety and Efficacy of Intravenous Tranexamic Acid Versus IV Carbetocin in Reducing Blood Loss During Abdominal Myomectomy: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT04357015
- Acronym / sponsor ID
- tranexamic acid myomectomy
- Conditions
- Myomectomy
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 153 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 1 May 2020 (estimated)
- Primary completion
- 10 Oct 2020 (estimated)
- Study completion
- 20 Oct 2020 (estimated)
- First posted
- 22 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
the aim of the present study is to compare safety and efficacy of intravenous tranexamic acid versus IV carbetocin in reducing blood loss during abdominal myomectomy: a randomized controlled trial
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| intravenous tranexamic acid | Experimental | Drug: intravenous tranexamic acidThe tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision |
| intravenous carbetocin | Active comparator | Drug: intravenous carbetocinThe carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision |
| placebo | Placebo comparator | Drug: placebothe placebo group will be given a normal saline IV bolus 20 minutes before surgical incision |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- women with symptomatic fibroids candidate for abdominal myomectomy with staging of myoma from (3 to 6) according to FIGO staging
Key exclusion criteria (1 listed)
- women with Myoma FIGO staging (1,2,7 and 8) candidate for laparoscopic or hysteroscopic myomectomy, women with allergy or contraindications to carbetocin or tranexamic acid
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| intravenous tranexamic acidThe tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision | Drug | intravenous tranexamic acid |
| intravenous carbetocinThe carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision | Drug | intravenous carbetocin |
| placebothe placebo group will be given a normal saline IV bolus 20 minutes before surgical incision | Drug | placebo |
Primary outcome
intraoperative blood loss
Time frame: one hour
the intraoperative blood loss in ml will be estimated during the procedure
1 secondary outcome
need for blood transfusion
Time frame: 24 hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2020.
Related trials for Myomectomy
Enrolling by invitation
Reducing Blood Loss During Myomectomy by Comparing Local Epinephrine and Uterine Artery Tourniquet During Procedure
Local Epinephrine in Myomectomy
Not yet recruiting
LapBox® Manual Containment System
Surgery
RecruitingPhase 4
QL Block in Laparoscopic Myomectomy
Postoperative Pain, Fibroid Uterus
Recruiting
Prevention of Intra-uterine Adhesions Following Laparoscopic and Laparotomic Myomectomy
Myoma
RecruitingObservational study
Outpatient Visits Versus Telehealth for Postoperative Care After Minimally Invasive Gynecologic Surgery
to Determine Whether Patient Satisfaction With Postoperative Telehealth Follow-up is Non-inferior to In-person Clinic Visits
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing intravenous tranexamic acid and intravenous carbetocin in people with Myomectomy, run by Cairo University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 22 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact AHMED SAMY (+201100681167, ahmedsamy8233@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
intraoperative blood loss (time frame: one hour). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2020.